388 related articles for article (PubMed ID: 27055020)
1. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
Gessner BD; Wilder-Smith A
Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].
Hernández-Ávila M; Lazcano-Ponce E; Hernández-Ávila JE; Alpuche-Aranda CM; Rodríguez-López MH; García-García L; Madrid-Marina V; López Gatell-Ramírez H; Lanz-Mendoza H; Martínez-Barnetche J; Díaz-Ortega JL; Ángeles-Llerenas A; Barrientos-Gutiérrez T; Bautista-Arredondo S; Santos-Preciado JI
Salud Publica Mex; 2016; 58(1):71-83. PubMed ID: 26879510
[TBL] [Abstract][Full Text] [Related]
3. Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.
Reynales H; Carrasquilla G; Zambrano B; Cortés S M; Machabert T; Jing J; Pallardy S; Haney O; Faccini M; Quintero J; Noriega F
Pediatr Infect Dis J; 2020 Apr; 39(4):e30-e36. PubMed ID: 32040014
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
[TBL] [Abstract][Full Text] [Related]
5. Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials.
Gailhardou S; Skipetrova A; Dayan GH; Jezorwski J; Saville M; Van der Vliet D; Wartel TA
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004821. PubMed ID: 27414655
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a tetravalent dengue vaccine in children in Latin America.
Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
[TBL] [Abstract][Full Text] [Related]
7. Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine.
El Fezzazi H; Branchu M; Carrasquilla G; Pitisuttithum P; Perroud AP; Frago C; Coudeville L
Am J Trop Med Hyg; 2017 Dec; 97(6):1898-1903. PubMed ID: 29141713
[TBL] [Abstract][Full Text] [Related]
8. Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.
Scott LJ
Drugs; 2016 Sep; 76(13):1301-1312. PubMed ID: 27506852
[TBL] [Abstract][Full Text] [Related]
9. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Hospitalized and Severe Dengue Cases Over the 6 years of Follow-up of the Tetravalent Dengue Vaccine (CYD-TDV) Efficacy Trials in Asia and Latin America.
Forrat R; Dayan GH; DiazGranados CA; Bonaparte M; Laot T; Capeding MR; Sanchez L; Coronel DL; Reynales H; Chansinghakul D; Hadinegoro SRS; Perroud AP; Frago C; Zambrano B; Machabert T; Wu Y; Luedtke A; Price B; Vigne C; Haney O; Savarino SJ; Bouckenooghe A; Noriega F
Clin Infect Dis; 2021 Sep; 73(6):1003-1012. PubMed ID: 33822015
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
[TBL] [Abstract][Full Text] [Related]
13. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
[TBL] [Abstract][Full Text] [Related]
14. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
Guy B; Briand O; Lang J; Saville M; Jackson N
Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
[TBL] [Abstract][Full Text] [Related]
17. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.
Dayan GH; Thakur M; Boaz M; Johnson C
Vaccine; 2013 Oct; 31(44):5047-54. PubMed ID: 24021313
[TBL] [Abstract][Full Text] [Related]
19. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Dorigatti I; Aguas R; Donnelly CA; Guy B; Coudeville L; Jackson N; Saville M; Ferguson NM
Vaccine; 2015 Jul; 33(31):3746-51. PubMed ID: 26051515
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
